UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus

Lupus, 2018-04, Vol.27 (4), p.564-571

2018

Volltextzugriff (PDF)

Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis

Clinical and experimental rheumatology, 2012-03, Vol.30 (2 Suppl 71), p.S17

2012

Volltextzugriff (PDF)

Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort

Arthritis research & therapy, 2020-03, Vol.22 (1), p.56-8, Article 56

2020

Volltextzugriff (PDF)

AB1028 Acth vs betamethasone for the treatment of acute gout in hospitalisedpatients An open label, comparative study

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1630

2018

Volltextzugriff (PDF)

Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients

Seminars in arthritis and rheumatism, 2021-02, Vol.51 (1), p.137-143

2021

Volltextzugriff (PDF)

SAT0281 Biologics in sapho syndrome. a systematic review

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1004

2018

Volltextzugriff (PDF)

OP0092 Decreased dickkopf-1 expression in clinically uninvolved skin from patients with systemic sclerosis

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.96

2018

Volltextzugriff (PDF)

THU0427 Comparable cardiovascular disease and neoplasm rates but higher frequency of depression in systemic sclerosis versus rheumatoid arthritis: a multicentre comparative study of comorbidities

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.426

2018

Volltextzugriff (PDF)

THU0455 Acth is Effective and Safe for the Treatment of Acute Calcium Pyrophosphate Crystal Arthritis in Hospitalized Patients

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A318-A318

2013

Volltextzugriff (PDF)

FRI0513 Decreased Skin Expression but Normal Circulating Levels and Function of Dickkopf-1 in Patients with Systemic Sclerosis

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.573-573

2014

Volltextzugriff (PDF)

FRI0514 Upregulation of Dickkopf-1 Skin Expression following B Cell Depletion Therapy Associates with Enhanced Resolution of Skin Fibrosis in Patients with Systemic Sclerosis

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.573-573

2014

Volltextzugriff (PDF)

SAT0308 Effective Suppression of Adp-Dependent Platelet Activation by Clopidogrel May Result in Clinical Stabilization in Patients with Systemic Sclerosis. Results of an Open Label, Proof of Concept Study

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.704-704

2014

Volltextzugriff (PDF)

AB1221 Acth as first line treatment for gout in hospitalized patients

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.707-707

2013

Volltextzugriff (PDF)

SAT0222 B Cell Depletion Therapy in Systemic Sclerosis Associated Interstitial Lung Disease. A Multicenter, Open Label, Comparative Study with A Follow up of 94 Patient-Years

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.749-749

2016

Volltextzugriff (PDF)

Cardiovascular risk factors and not disease activity, severity or therapy associate with renal dysfunction in patients with rheumatoid arthritis

Annals of the rheumatic diseases, 2010-03, Vol.69 (3), p.517-521

2010

Volltextzugriff (PDF)

THU0342 Anti-TNF Treatment Reduces Serum Serotonin Levels in Patients with Ankylosing Spondylitis and Downregulates Serotonin Signaling in an Experimental Cell Line Model

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A280-A281

2013

Volltextzugriff (PDF)

SAT0450 Rituximab in Systemic Sclerosis. Results of an up to Seven Years, Open Label, Multicenter Study with a Follow-up of 89 Patient-Years

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.823-823

2015

Volltextzugriff (PDF)

Anti-TNF-α induced paradoxical psoriasis in patients with ankylosing spondylitis: a systematic review

Clinical and experimental rheumatology, 2024-01, Vol.42 (1), p.178

2024

Volltextzugriff (PDF)

FRI0408 Rituximab treatment reduces circulating th2 cells and il4 expression in the skin of patients with systemic sclerosis

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A511-A511

2013

Volltextzugriff (PDF)

OP0242 Serum Indian Hedgehog (IHH) Levels Are Increased in Patients with Ankylosing Spondylitis (AS). Anti-TNF a Treatment Decreases Serum IHH Levels in Patients with as and Affects the Expression of Functional Target Genes in a Cell Line Model

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A134-A134

2013

Volltextzugriff (PDF)

THU0245 Rituximab has a beneficial effect on lung function and skin fibrosis in patients with systemic sclerosis. An open label study

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.237-238

2013

Volltextzugriff (PDF)

Experience with infliximab (anti-TNFα monoclonal antibody) as monotherapy for giant cell arteritis

Annals of the rheumatic diseases, 2003-11, Vol.62 (11), p.1116-1116

2003

Volltextzugriff (PDF)

PBI20 SECUKINUMAB VS. ADALIMUMAB AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM A GREEK PERSPECTIVE

Value in health, 2019-11, Vol.22, p.S420-S421

2019

Volltextzugriff (PDF)

Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis

Rheumatology (Oxford, England), 2007-02, Vol.46 (2), p.227-231

2007

Volltextzugriff (PDF)

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

Rheumatology (Oxford, England), 2010-02, Vol.49 (2), p.271-280

2010

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(59)
Tagungsberichte
(2)

Sprache

Englisch
(57)
Französisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(32)
Life Sciences & Biomedicine
(31)
Humans
(29)
Rheumatology
(28)
Male
(16)
Female
(13)
Middle Aged
(13)
Systemic Sclerosis
(12)
Adult
(10)
Biological And Medical Sciences
(9)
Diseases Of The Osteoarticular System
(9)
Fibrosis
(9)
Medical Sciences
(9)
Scleroderma
(9)
Treatment Outcome
(9)
Aged
(8)
Animals
(7)
Antirheumatic Agents - Therapeutic Use
(7)
Patients
(7)
Rituximab
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus

Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis

Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort

AB1028 Acth vs betamethasone for the treatment of acute gout in hospitalisedpatients An open label, comparative study

Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients

SAT0281 Biologics in sapho syndrome. a systematic review

OP0092 Decreased dickkopf-1 expression in clinically uninvolved skin from patients with systemic sclerosis

THU0427 Comparable cardiovascular disease and neoplasm rates but higher frequency of depression in systemic sclerosis versus rheumatoid arthritis: a multicentre comparative study of comorbidities

THU0455 Acth is Effective and Safe for the Treatment of Acute Calcium Pyrophosphate Crystal Arthritis in Hospitalized Patients

FRI0513 Decreased Skin Expression but Normal Circulating Levels and Function of Dickkopf-1 in Patients with Systemic Sclerosis

FRI0514 Upregulation of Dickkopf-1 Skin Expression following B Cell Depletion Therapy Associates with Enhanced Resolution of Skin Fibrosis in Patients with Systemic Sclerosis

SAT0308 Effective Suppression of Adp-Dependent Platelet Activation by Clopidogrel May Result in Clinical Stabilization in Patients with Systemic Sclerosis. Results of an Open Label, Proof of Concept Study

AB1221 Acth as first line treatment for gout in hospitalized patients

SAT0222 B Cell Depletion Therapy in Systemic Sclerosis Associated Interstitial Lung Disease. A Multicenter, Open Label, Comparative Study with A Follow up of 94 Patient-Years

Cardiovascular risk factors and not disease activity, severity or therapy associate with renal dysfunction in patients with rheumatoid arthritis

THU0342 Anti-TNF Treatment Reduces Serum Serotonin Levels in Patients with Ankylosing Spondylitis and Downregulates Serotonin Signaling in an Experimental Cell Line Model

SAT0450 Rituximab in Systemic Sclerosis. Results of an up to Seven Years, Open Label, Multicenter Study with a Follow-up of 89 Patient-Years

Anti-TNF-α induced paradoxical psoriasis in patients with ankylosing spondylitis: a systematic review

FRI0408 Rituximab treatment reduces circulating th2 cells and il4 expression in the skin of patients with systemic sclerosis

OP0242 Serum Indian Hedgehog (IHH) Levels Are Increased in Patients with Ankylosing Spondylitis (AS). Anti-TNF a Treatment Decreases Serum IHH Levels in Patients with as and Affects the Expression of Functional Target Genes in a Cell Line Model

THU0245 Rituximab has a beneficial effect on lung function and skin fibrosis in patients with systemic sclerosis. An open label study

Experience with infliximab (anti-TNFα monoclonal antibody) as monotherapy for giant cell arteritis

PBI20 SECUKINUMAB VS. ADALIMUMAB AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM A GREEK PERSPECTIVE

Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

Suchergebnisse filtern